Neogenomics Inc   (NEO)
Other Ticker:  
    Sector  Technology    Industry IT Infrastructure
   Industry IT Infrastructure
   Sector  Technology
Price: $14.5100 $-0.23 -1.560%
Day's High: $14.89 Week Perf: -2.16 %
Day's Low: $ 14.48 30 Day Perf: 11.53 %
Volume (M): 625 52 Wk High: $ 21.22
Volume (M$): $ 9,070 52 Wk Avg: $15.07
Open: $14.81 52 Wk Low: $11.03

 Market Capitalization (Millions $) 1,830
 Shares Outstanding (Millions) 126
 Employees 2,000
 Revenues (TTM) (Millions $) 610
 Net Income (TTM) (Millions $) -84
 Cash Flow (TTM) (Millions $) 56
 Capital Exp. (TTM) (Millions $) 24

Neogenomics Inc
We run a network of cancer testing labs in the United States, Europe, and Asia. Our objective is to improve patient care by providing outstanding cancer-focused diagnostic services. Our aim is to be the worlds premier cancer testing and information company by providing unrivaled quality, great service, and cutting-edge solutions.

Cytogenetics ('karyotype analysis') ' the study of normal and abnormal chromosomes and their relationship to disease. Cytogenetics involves analyzing the chromosome structure to identify changes from patterns seen in normal chromosomes. Cytogenetic studies are often performed to provide diagnostic, prognostic and occasionally predictive information for patients with hematological malignancies.
Fluorescence In-Situ Hybridization ('FISH') ' a molecular cytogenetic technique that focuses on detecting and localizing the presence or absence of specific DNA sequences and genes on chromosomes. The technique uses fluorescent probes that bind to only those parts of the chromosome with which they show a high degree of sequence similarity. Fluorescence microscopy is used to visualize the fluorescent probes bound to the chromosomes. FISH can be used to help identify numerous types of gene alterations, including amplifications, deletions, and translocations.
Flow cytometry ' a technique utilized to measure the characteristics of cell populations. Typically performed on liquid samples such as peripheral blood and bone marrow aspirate, it may also be performed on solid tissue samples such as lymph nodes following additional processing steps. Cells are labeled with selective fluorescent antibodies and analyzed as they flow in a fluid stream through a beam of light. The properties measured in these antibodies include the relative size, relative granularity or internal complexity, and relative fluorescence intensity. These fluorescent antibodies bind to specific cellular antigens and are used to identify abnormal and/or malignant cell populations. Flow cytometry is typically utilized in diagnosing a wide variety of hematopoietic and lymphoid neoplasms. Flow cytometry is also used to monitor patients during the course of therapy to identify extremely low levels of residual malignant cells, known as minimal residual disease ('MRD') monitoring.
Immunohistochemistry ('IHC') and Digital Imaging ' the process of localizing cellular proteins in tissue sections and relies on the principle of antigen-antibody binding. IHC is widely used in the diagnosis of abnormal cells such as those found in cancer. Specific surface membrane, cytoplasmic, or nuclear markers may be identified. IHC is also widely used to understand the distribution and localization of differentially expressed proteins. Digital imaging allows clients to visualize scanned slides and also perform quantitative analysis for certain stains. Scanned slides are received online in real time and can be previewed often a full day before the glass slides can be shipped back to clients.
Molecular testing ' a rapidly growing field which includes a broad range of laboratory techniques utilized in cancer testing. Most molecular techniques rely on the analysis of DNA and/or RNA, as well as the structure and function of genes at the molecular level. Molecular testing technologies include: liquid biopsy tests for advanced non-small cell lung cancer, all solid tumor types (pan-cancer), and certain breast cancer cases; DNA fragment length analysis; polymerase chain reaction ('PCR') analysis; reverse transcriptase polymerase chain reaction ('RT-PCR') analysis, real-time (or quantitative) polymerase chain reaction ('qPCR') analysis; bi-directional Sanger sequencing analysis; and next-generation sequencing ('NGS') analysis.
Morphologic analysis ' the process of analyzing cells under the microscope by a pathologist, usually for the purpose of diagnosis. Morphologic analysis may be performed on a wide variety of samples, such as peripheral blood, bone marrow, lymph node, and from other sites such as lung, breast, etc. The services provided at NeoGenomics may include primary diagnosis, in which a sample is received for processing and our pathologists provide the initial diagnosis; or may include secondary consultations, in which slides and/or tissue blocks are received from an outside institution for second opinion. In the latter setting, the expert pathologists at NeoGenomics assist our client pathologists on their most difficult and complex cases.
The clinical cancer testing services we offer to community-based pathologists are designed to be a natural extension of, and complementary to, the services that they perform within their own practices. We believe our relationship as a non-competitive partner to community-based pathology practices, hospital pathology labs, reference labs, and academic centers can empower them to expand their breadth of testing to provide a menu of services that could match or exceed the level of service found in any center of excellence around the world. Community-based pathology practices and hospital pathology labs may order certain testing services on a technical component only ('TC' or 'tech-only') basis, which allows them to participate in the diagnostic process by performing the professional component ('PC') interpretation services without having to hire laboratory technologists or purchase the sophisticated equipment needed to perform the technical component of the tests. We also support our pathology clients with interpretation and consultative services using our own specialized team of pathologists for difficult or complex cases and we provide overflow interpretation services when requested by clients.

We are is a leading provider of Molecular and NGS testing. These tests are interpreted by NeoGenomics' team of Molecular experts and are often ordered in conjunction with other testing modalities. NGS panels are one of our fastest growing testing areas and clients can often receive a significant amount of biomarker information from very limited samples. These comprehensive panels can allow for faster treatment decisions for patients as compared to a series of single-gene molecular tests being ordered sequentially. We have one of the broadest Molecular menus in the industry and our targeted NeoTYPE panels include genes relevant to a particular cancer type, as well as other complementary tests such as IHC and FISH. In addition, we offer molecular-only NGS targeted and comprehensive panels which combine DNA and RNA into a single work stream in order to report a full spectrum of genomic alterations, including mutation, fusions, copy number variations, and gene expression. This comprehensive menu means that NeoGenomics can be a 'one-stop shop' for our clients who can get all of their oncology testing needs satisfied by our laboratory. This is attractive to our clients as patient samples do not need to be split and then managed across several laboratories. The acquisition of Inivata, provided us with oncology Liquid Biopsy technology capabilities. InVisionFirst'-Lung is a highly sensitive, targeted plasma-based assay for patients with non-small cell lung cancer, and RaDaR' is an industry-leading liquid biopsy assay designed to detect residual disease and recurrence in plasma samples from patients with solid tumor malignancies. We expect our Molecular laboratory and NGS capabilities to be a key growth driver in the coming years.

Our Pharma Services revenue consists of the following three revenue streams:
Clinical trials and research;
Validation laboratory services; and
Our Pharma Services segment supports pharmaceutical firms in their drug development programs by supporting various clinical trials and research. This portion of our business often involves working with the pharmaceutical firms ('sponsors') on study design as well as performing the required testing. Our medical team often advises the sponsor and works closely with them as specimens are received from the enrolled sites. We also work on developing tests that will be used as part of a companion diagnostic to determine patients' response to a particular drug. As studies unfold, our clinical trials team reports the data and often provides key analysis and insights back to the sponsors.
Our Pharma Services segment provides comprehensive testing services in support of our pharmaceutical clients' oncology programs from discovery to commercialization. In biomarker discovery, our aim is to help our customers discover the right content. We help our customers develop a biomarker hypothesis by recommending an optimal platform for molecular screening and backing our discovery tools with the informatics to capture meaningful data. In other pre-clinical and non-clinical work, we can use our platforms to characterize markers of interest. Moving from discovery to development, we seek to help our customers refine their biomarker strategy and, if applicable, develop a companion diagnostic pathway using the optimal technology for large-scale clinical trial testing.

   Company Address: 9490 NeoGenomics Way, Fort Myers, 33912 FL
   Company Phone Number: 768-0600   Stock Exchange / Ticker: NASDAQ NEO

Customers Net Income grew by NEO's Customers Net Profit Margin grew to

44.29 %

3.89 %

• Customers Performance • Customers Expend. • Customers Efficiency • List of Customers


Stock Performances by Major Competitors

5 Days Decrease / Increase
DGX   -1.16%    
LH   -1.93%    
• View Complete Report

Neogenomics Inc

Neogenomics Inc Reports Strong Revenue Growth in First Quarter but Fails to Achieve Profitability

Neogenomics Inc, a leading company in the Electronic Instruments & Controls sector, has reported a significant increase in revenue in their first quarter 2024 financial report. Despite a challenging market environment, NEOs managed to achieve a revenue growth of 13.299% compared to the same quarter the previous year, totaling $155.47 million.
However, this positive revenue growth was offset by a loss of $-0.21 per share, highlighting the financial challenges faced by the company. This loss per share is an increase from the previous quarter, where the loss stood at $-0.11 per share.

Neogenomics Inc

Neogenomics Inc Shows Strong Top-line Progress in Q4 2023

Neogenomics Inc, a leader in the Electronic Instruments & Controls industry, continues to impress investors with its recent financial performance. The company has shown significant improvement in key metrics such as earnings per share, revenue growth, and net deficit.
In the most recent fiscal period, Neogenomics Inc reported a decrease in loss per share to $-0.11 compared to $-0.18 a year prior. Additionally, EPS improved from $-0.15 in the previous reporting period. This positive trend is a reflection of the company's dedication to advancing and growing its business in a competitive market.

Neogenomics Inc

Revised headline: Neogenomics Inc's third quarter of 2023 financial report showcases remarkable resilience and improved profitability amidst sector challenges

As the third quarter of 2023 came to a close, Neogenomics Inc, a leading company in the Electronic Instruments & Controls sector, showcased remarkable financial results. Despite the sector facing numerous challenges, Neogenomics Inc emerged as a standout performer, providing investors with confidence in its ability to navigate a difficult climate.
The financial results for the July to September 30, 2023 period revealed an impressive decline in loss per share, dropping from $-0.30 to $-0.15 when compared to the same period the previous year. Moreover, the company's earnings per share (EPS) showed progress, improving from $-0.19 in the prior reporting season. These results indicate a positive trajectory for Neogenomics Inc's profitability.

Neogenomics Inc

Neogenomics Inc reports outstanding financial performance, reducing losses and increasing profitability by 32% in Q2 2023!

As a stock market journalist, I have been closely analyzing the financial results of Neogenomics Inc for the period ending June 30, 2023. The company has shown some positive improvements in its performance compared to the prior year.
One significant highlight is the decrease in loss per share from $-0.28 to $-0.19 as compared to the previous year. Additionally, there has been an improvement in earnings per share from $-0.25 to a better position. These numbers indicate that Neogenomics Inc has managed to reduce its losses and increase its profitability during this period.

Neogenomics Inc

Electronic Instruments & Controls Company Records Impressive Double-Digit Revenue Growth in the First Quarter Ending March 31, 2023

Investors should exercise caution when considering investing in Neogenomics Inc. Based on the first quarter of 2023 earnings season, the company reported a net loss of $-0.25 per share, an improvement from the prior year but a decline from the prior financial reporting period. While revenue increased by 17.113% to $137.22 million from the prior year, the sequential decrease of -1.071% from the previous quarter may be cause for concern. Additionally, the company reported a net loss of $-30.795 million for the quarter, compared to a net loss of $-49.408 million in the prior year period.
It is important for investors to closely monitor the company's financial performance and take note of any warning signs, such as declining revenue or increasing expenses. The upcoming financial earnings report, expected on August 08, 2023, should be closely watched to determine whether the company is on a path to profitability or if there are additional concerns that need to be addressed.


Neogenomics Inc's Segments
• View Complete Report
  Company Estimates  
  Revenue Outlook
Neogenomics Inc does not provide revenue guidance.

Earnings Outlook
Neogenomics Inc does not provide earnings estimates.

Geographic Revenue Dispersion


About us


CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com